Azitra (AZTR) Other Non-Current Assets (2022 - 2026)
Azitra's (AZTR) quarterly Other Non-Current Assets came in at $47228.0 in Q1 2026, up 0.61% YoY from $46942.0 in Q1 2025, and little changed on a QoQ basis from $47402.0 in Q4 2025.
Azitra (AZTR) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Other Non-Current Assets data on file, last reported at $47228.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 0.61% year-over-year to $47228.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47228.0 (up 0.61% YoY) and the FY2025 annual result came in at $47402.0, up 0.98% from the prior year.
- Other Non-Current Assets steadied at $47228.0 in Q1 2026, from $47402.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $2.2 million in Q2 2023 to a low of $46941.0 in Q4 2024.
- A 5-year average of $353635.8 and a median of $47409.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets slumped 97.83% — and 2025, when it rose 0.98%.
- Tracing AZTR's Other Non-Current Assets over 5 years: stood at $47507.0 in 2022, then rose by 0.53% to $47760.0 in 2023, then decreased by 1.71% to $46941.0 in 2024, then rose by 0.98% to $47402.0 in 2025, then dropped by 0.37% to $47228.0 in 2026.
- The last three Other Non-Current Assets figures came in at $47228.0 (Q1 2026), $47402.0 (Q4 2025), and $47239.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 150,965.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47,042.00 |
| Mar 31, 2026 | 47,228.00 |
| Dec 31, 2025 | 47,402.00 |
| Sep 30, 2025 | 47,239.00 |
| Jun 30, 2025 | 47,409.00 |
| Mar 31, 2025 | 46,942.00 |
| Dec 31, 2024 | 46,941.00 |
| Sep 30, 2024 | 47,531.00 |
| Jun 30, 2024 | 47,404.00 |
| Mar 31, 2024 | 47,541.00 |
| Dec 31, 2023 | 47,760.00 |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Dec 31, 2022 | 47,507.00 |